Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV

References

• The Thai Working Group on Burden of Disease and Injuries. Burden of disease and injuries in Thailand; 2002.
   Google Scholar
• Country factsheets Thailand; 2019. Available from: https://www.unaids.org/en/regionscountries/countries/Thailand. Accessed April 6, 2021.
   Google Scholar
• HIV Epidemic. Available from: https://hivhub.ddc.moph.go.th/epidemic.php. Accessed April 6, 2021.
   Google Scholar
• Manosuthi W, Ongwandee S, Bhakeecheep S, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12:12. doi:10.1186/s12981-015-0053-z
   PubMed Web of Science ®Google Scholar
• Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 6, 2021.
   Google Scholar
• Department of Disease Control, Ministry of Public Health. Thailand National Guidelines on HIV/AIDS Diagnosis, Treatment and Prevention 2020/2021. Thailand: Department of Disease Control, Ministry of Public Health; 2020.
   Google Scholar
• Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 2006;6(4):234–245. doi:10.1038/sj.tpj.6500374
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572. doi:10.1002/cpt.2350
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and Abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18(1):68–76. doi:10.18433/j39s3t
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Table of pharmacogenetic associations. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations. Accessed July 28, 2020.
   Google Scholar
• Wang C-W, Tassaneeyakul W, Chen C-B, et al. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. J Allergy Clin Immunol. 2021;147(4):1402–1412. doi:10.1016/j.jaci.2020.08.003
   PubMed Web of Science ®Google Scholar
• Sukasem C, Pratoomwun J, Satapornpong P, et al. Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes. Clin Pharmacol Ther. 2020;108(5):1078–1089. doi:10.1002/cpt.1915
   PubMed Web of Science ®Google Scholar
• Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16(5):589–595. doi:10.5588/ijtld.11.0377
   PubMed Web of Science ®Google Scholar
• Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(3):293–305. doi:10.5588/ijtld.18.0324
   PubMed Web of Science ®Google Scholar
• Sukasem C, Jantararoungtong T, Koomdee N. Pharmacogenomics research and its clinical implementation in Thailand: lessons learned from the resource-limited settings. Drug Metab Pharmacokinet. 2021;39:100399. doi:10.1016/j.dmpk.2021.100399
   PubMed Web of Science ®Google Scholar
• Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics. 2010;11(5):643–646. doi:10.2217/pgs.10.45
   PubMed Web of Science ®Google Scholar
• Department of Medical Services; Ministry of Public Health AND Infectious Disease Association of Thailand. Clinical Practice Guideline (CPG) of Tuberculosis Treatment in Thailand. Department of Medical Services; Ministry of Public Health; 2018.
   Google Scholar
• Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498. doi:10.1056/NEJMra032588
   PubMed Web of Science ®Google Scholar
• Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316(26):1627–1632. doi:10.1056/nejm198706253162604
   PubMed Web of Science ®Google Scholar
• Awad WB, Asaad A, Al-Yasein N, Najjar R. Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study. BMC Infect Dis. 2020;20(1):400. doi:10.1186/s12879-020-05127-y
   PubMed Web of Science ®Google Scholar
• Crozier F. Pneumocystis carinii pneumonia prophylaxis: current therapies and recommendations. J Pediatr Oncol Nurs. 2011;28(3):179–184. doi:10.1177/1043454211408101
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach. World Health Organization; 2006.
   Google Scholar
• World Health Organization. Guidelines for treatment of tuberculosis, 4th ed. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed July 1, 2021.
   Google Scholar
• Department of Disease Control, Ministry of Public Health. Thailand National Guidelines on TB/HIV 2017. Thailand: Department of Disease Control, Ministry of Public Health; 2020.
   Google Scholar
• Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–1101. doi:10.1007/s00228-012-1429-9
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733–1738. doi:10.1128/aac.49.5.1733-1738.2005
   PubMed Web of Science ®Google Scholar
• Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol. 2007;63(10):927–933. doi:10.1007/s00228-007-0333-1
   PubMed Web of Science ®Google Scholar
• Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. World Health Organization; 2003.
   Google Scholar
• Chaikledkaew U, Teerawattananon Y. Guidelines for Health Technology Assessment in Thailand. 2nd ed. Nonthaburi: Wacharin Publications; 2013.
   Google Scholar
• Admera Health PGxOne™ Plus. Genetic testing registry. NCBI. Available from: https://www.ncbi.nlm.nih.gov/gtr/tests/567653/performance-characteristics/. Accessed September 7, 2021.
   Google Scholar
• Ningsanon P, Supawitkul S, Srisongsom S, Boason T, Nutchom K. CD4 monitoring in HIV infected patients not eligible for receiving ARV in 2004–2006. Dis Control J. 2008;34(1):11–21.
   Google Scholar
• Rojanawiwat A, Tsuchiya N, Pathipvanich P, et al. Impact of the National Access to Antiretroviral Program on the incidence of opportunistic infections in Thailand. Int Health. 2011;3(2):101–107. doi:10.1016/j.inhe.2010.12.004
   PubMed Web of Science ®Google Scholar
• Wattanapokayakit S, Mushiroda T, Yanai H, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberc Lung Dis. 2016;20(10):1364–1369. doi:10.5588/ijtld.15.0310
   PubMed Web of Science ®Google Scholar
• Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429–437. doi:10.1097/fpc.0000000000000306
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to Abacavir. N Engl J Med. 2008;358(6):568–579. doi:10.1056/NEJMoa0706135
   PubMed Web of Science ®Google Scholar
• Leelahavarong P, Teerawattananon Y, Werayingyong P, et al. Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. BMC Public Health. 2011;11:534. doi:10.1186/1471-2458-11-534
   PubMed Web of Science ®Google Scholar
• Maleewong U, Kulsomboon V, Teerawattananon Y. The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. J Med Assoc Thai. 2008;91(Suppl 2):S126–38.
   PubMedGoogle Scholar
• Leelukkanaveera Y. An Economic Evaluation of Routine Offer HIV Counseling and Testing of Out Patients at Community Hospitals in Thailand. Chulalongkorn University; 2009.
   Google Scholar
• Plumpton CO, Yip VL, Alfirevic A, Marson AG, Pirmohamed M, Hughes DA. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56(4):556–563. doi:10.1111/epi.12937
   PubMed Web of Science ®Google Scholar
• Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1-14; quiz 706–708. doi:10.1016/j.jaad.2013.01.033
   Web of Science ®Google Scholar
• Mo P, Zhu Q, Teter C, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014;28:95–100. doi:10.1016/j.ijid.2014.06.020
   PubMed Web of Science ®Google Scholar
• Ministry of Commerce. Report for consumer price index of Thailand. Available from: http://www.indexpr.moc.go.th/price_present/TableIndexG_region.asp?table_name=cpig_index_country&province_code=5&type_code=g&check_f=i&year_base=2562&nyear=2552. Accessed June 1, 2021.
   Google Scholar
• Ministry of Public Health. Drug And Medical Supply Information Center. Available from: http://dmsic.moph.go.th/index/drugsearch/1. Accessed September 1, 2021.
   Google Scholar
• Department of Medical Sciences MoPH. Service fee for analysis and service. Availabe from: https://www3.dmsc.moph.go.th/. Accessed September 1, 2021.
   Google Scholar
• Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11(7):1144–1153. doi:10.1111/j.1524-4733.2008.00326.x
   PubMed Web of Science ®Google Scholar
• Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health. 2013;16(1):66–75. doi:10.1016/j.jval.2012.09.006
   PubMed Web of Science ®Google Scholar
• Wolf E, Blankenburg M, Bogner JR, et al. Cost impact of prospective HLA-B*5701-screening prior to Abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res. 2010;15(4):145–151. doi:10.1186/2047-783X-15-4-145
   PubMed Web of Science ®Google Scholar
• Kapoor R, Martinez-Vega R, Dong D, et al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before Abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics. 2015;25(2):60–72. doi:10.1097/fpc.0000000000000107
   PubMed Web of Science ®Google Scholar
• Satapornpong P, Jinda P, Jantararoungtong T, et al. Genetic diversity of HLA class I and Class II alleles in Thai populations: contribution to genotype-guided therapeutics. Front Pharmacol. 2020;11:78. doi:10.3389/fphar.2020.00078
   PubMed Web of Science ®Google Scholar
• Retno WS, Kinasih P, Intan R, Syukrini B, Rika Y. High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer. Med J Indones. 2017;26(1). doi:10.13181/mji.v26i1.1563
   Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038–1046. doi:10.1086/424009
   PubMed Web of Science ®Google Scholar
• Goris A, Walton A, Ban M, Dubois B, Compston A, Sawcer S. A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens. 2008;72(4):401–403. doi:10.1111/j.1399-0039.2008.01101.x
   PubMedGoogle Scholar
• Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162(8):921–928. doi:10.1001/archinte.162.8.921
   PubMed Web of Science ®Google Scholar
• Rebecca E. Sanger sequencing: past successes and current applications. Available from: https://www.cytivalifesciences.com/en/us/news-center/sanger-sequencing-past-and-present-10001. Accessed May 22, 2021.
   Google Scholar
• Reslova N, Michna V, Kasny M, Mikel P, Kralik P. xMAP technology: applications in detection of pathogens. Front Microbiol. 2017;8:55. doi:10.3389/fmicb.2017.00055
   PubMed Web of Science ®Google Scholar